MedWatch

Scandinavian life science cluster praises "significant" Novo decision to invest in Denmark

Industry organization Medicon Valley Alliance is pleased that Novo Nordisk has decided to invest in its production facilities in Denmark.

Anette Steenberg, CEO, Medicon Valley Alliance. | Photo: Copenhagen Capacity / PR

Novo Nordisk has decided to invest DKK 5.4m (USD 744.4m) in its Danish production facilities, and this is important for Denmark, says Anette Steenberg, CEO of Medicon Valley Alliance.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs